密歇根州

我们是谁

  • 4 月 5, 2022
    MRTX849 治疗 KRAS G12C 基因突变癌症患者的 1/2 期研究 KRYSTAL-1
  • 4 月 5, 2022
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
  • 4 月 5, 2022
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
  • 4 月 5, 2022
    Repotrectinib（TPX-0005）对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究
  • 4 月 5, 2022
    TAPUR：测试食品药品管理局（FDA）批准的针对晚期癌症患者肿瘤基因特定异常的药物的使用情况
  • 4 月 5, 2022
    REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors
  • 4 月 5, 2022
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
  • 4 月 5, 2022
    Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
  • 4 月 5, 2022
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
  • 4 月 5, 2022
    A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)